Seeking Novel Drug Candidates and Targets for Progressive Fibrosing Interstitial Lung Diseases and Acute Respiratory Distress Syndrome

CSL is interested in respiratory therapeutics in the areas of Interstitial Lung Diseases (ILD) and Acute Respiratory Distress Syndrome (ARDS). 

For ILD‑related research, halting and reversing fibrosis is a key element of interest. For ARDS‑related research, a focus on Community Acquired Pneumonia (CAP) is of key importance.

Approaches of Particular Interest

• Biologics and Antibody Therapeutics will be prioritized
• Cell and Gene Therapies

Developmental Stage

Validation with patient data, biomarkers, and/or in animal models preferable. Ex vivo models (e.g. human lung tissue) are also of high interest. Multi-omics data approaches welcome.

Submission Information

One‑page research summaries are encouraged, plus any relevant non‑confidential supporting documents 

Out of Scope

Small molecule approaches are not of interest, with RNA approaches being of low interest

Opportunity for Collaboration

CSL is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case by case basis. Example outcomes include licensing assets, or research collaborations (such as the creation of a joint steering committee consisting of academics and industry experts in the field at CSL).